Kooman & Associates’s GSK GSK Stock Holding History

Kooman & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$298K	Hold	5,692	–	–	0.08%	46
2026 Q1	$314K	Sell	5,692 -1,562	-22%	-$84.6K	0.09%	40
2025 Q4	$356K	Sell	7,254 -561	-7%	-$26.2K	0.11%	38
2025 Q3	$337K	Sell	7,815 -19	-0.2%	-$742	0.1%	40
2025 Q2	$301K	Buy	7,834 +2,142	+38%	+$81.8K	0.1%	41
2025 Q1	$221K	Buy	+5,692	New	+$208K	0.08%	45
2024 Q4	–	Sell	-6,229	Closed	-$255K	–	49
2024 Q3	$255K	Hold	6,229	–	–	0.09%	40
2024 Q2	$240K	Hold	6,229	–	–	0.1%	37
2024 Q1	$267K	Sell	6,229 -40	-0.6%	-$1.65K	0.11%	33
2023 Q4	$232K	Buy	6,269 +40	+0.6%	+$1.44K	0.1%	36
2023 Q3	$226K	Hold	6,229	–	–	0.11%	35
2023 Q2	$222K	Sell	6,229 -47	-0.7%	-$1.69K	0.11%	37
2023 Q1	$223K	Buy	6,276 +582	+10%	+$20.4K	0.12%	36
2022 Q4	$200K	Buy	+5,694	New	+$190K	0.2%	39

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kooman & Associates's GSK Position: Q2 2026 in Review

Kooman & Associates held its GSK (GSK) position steady in Q2 2026 at 5,692 shares worth $298K. The position accounts for 0.08% of the portfolio, ranked #46.

Kooman & Associates first reported a position in GSK in Q4 2022 and has held it in 14 quarters since. The position peaked at $356K in Q4 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Kooman & Associates held 5,692 shares of GSK worth $298K as of Q2 2026.
Kooman & Associates left its GSK share count unchanged in Q2 2026.
GSK made up 0.08% of Kooman & Associates's portfolio in Q2 2026, its #46 holding.
Kooman & Associates first reported a position in GSK in Q4 2022 and has held it in 14 quarters since.
Kooman & Associates's GSK position peaked at $356K in Q4 2025.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kooman & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.